New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy
Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical chall...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2016
|
| In: |
Clinical cancer research
Year: 2016, Jahrgang: 22, Heft: 1, Pages: 9-15 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-15-0820 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-15-0820 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/22/1/9 
|
| Verfasserangaben: | Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1728603331 | ||
| 003 | DE-627 | ||
| 005 | 20230428032953.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200902s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-15-0820 |2 doi | |
| 035 | |a (DE-627)1728603331 | ||
| 035 | |a (DE-599)KXP1728603331 | ||
| 035 | |a (OCoLC)1341358271 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 245 | 1 | 0 | |a New strategies in prostate cancer |b prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy |c Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut |
| 264 | 1 | |c January 2016 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.09.2020 | ||
| 520 | |a Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable and novel therapeutic approaches for palliation and increase of survival are needed. In this article, we discuss the recent development for noninvasive detection of recurrent disease and therapy of mCRPC with corresponding PSMA-targeted radioligands. Clin Cancer Res; 22(1); 9-15. ©2016 AACR. | ||
| 700 | 1 | |a Eder, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kopka, Klaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Babich, John W. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eisenhut, Michael |e VerfasserIn |0 (DE-588)1113306122 |0 (DE-627)867174501 |0 (DE-576)160846080 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 22(2016), 1, Seite 9-15 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a New strategies in prostate cancer prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:1 |g pages:9-15 |g extent:8 |a New strategies in prostate cancer prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-15-0820 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/22/1/9 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200902 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1113306122 |a Eisenhut, Michael |m 1113306122:Eisenhut, Michael |d 910000 |d 911400 |e 910000PE1113306122 |e 911400PE1113306122 |k 0/910000/ |k 1/910000/911400/ |p 5 |y j | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 1 |x j | ||
| 999 | |a KXP-PPN1728603331 |e 3746030110 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"January 2016","dateIssuedKey":"2016"}],"relHost":[{"name":{"displayForm":["American Association for Cancer Research"]},"recId":"325489971","id":{"zdb":["2036787-9"],"issn":["1557-3265"],"eki":["325489971"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}],"origin":[{"publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisher":"AACR"}],"part":{"text":"22(2016), 1, Seite 9-15","issue":"1","pages":"9-15","extent":"8","year":"2016","volume":"22"},"language":["eng"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1995 -"],"corporate":[{"display":"American Association for Cancer Research","role":"isb"}],"disp":"New strategies in prostate cancer prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapyClinical cancer research","type":{"media":"Online-Ressource","bibl":"periodical"}}],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1158/1078-0432.CCR-15-0820"],"eki":["1728603331"]},"title":[{"title":"New strategies in prostate cancer","subtitle":"prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy","title_sort":"New strategies in prostate cancer"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 02.09.2020"],"recId":"1728603331","person":[{"family":"Haberkorn","role":"aut","given":"Uwe","display":"Haberkorn, Uwe"},{"display":"Eder, Matthias","given":"Matthias","family":"Eder","role":"aut"},{"family":"Kopka","role":"aut","given":"Klaus","display":"Kopka, Klaus"},{"given":"John W.","display":"Babich, John W.","family":"Babich","role":"aut"},{"display":"Eisenhut, Michael","given":"Michael","role":"aut","family":"Eisenhut"}],"language":["eng"],"name":{"displayForm":["Uwe Haberkorn, Matthias Eder, Klaus Kopka, John W. Babich, and Michael Eisenhut"]}} | ||
| SRT | |a HABERKORNUNEWSTRATEG2016 | ||